The retinoblastoma susceptibility gene, RB, is a prototypic tumor suppressor gene. It has been shown to be involved fundamentally in the genesis of the intraocular childhood tumor retinoblastoma, as well as in a number of other human tumors. For the past eight years, we have isolated the retinoblastoma gene - the first human tumor suppressor gene, then shown that Rb gene replacement in many cultured tumor cells containing mutated RB alleles suppresses the cells' neoplastic properties. These results provided an initial basis for considering treatment of clinical cancer by replacing the wild-type Rb gene. To extend this cancer suppression concept to intact tumors in vivo, we have established a line of mice harboring RB mutations in the germline. Mice heterozygous for the mutant gene predictably develop specific cancers of the pituitary gland intermediate lobe with nearly 100% penetrance which mimics the natural human tumor formation. All these work set up a stage for us to finally test whether the tumor suppressor genes can be of use in clinical application. The experiment described in this proposal is an essential step before clinical applications can be sought. First, viral or nonviral vectors for efficient Rb gene delivery will be developed. Second, cell lines derived from mouse pituitary tumors will be established. Then the Rb gene delivery vectors will be tested, ex vivo and in vivo, using in situ labeling to demonstrate RB expression in targeted tumors, and magnetic resonance imaging and tumor markers to determine the effects of therapy on tumor growth. Third, the molecular events of tumor progression will be examined to define precisely the best therapeutic window for intervention. The concept of cancer suppression by the RB gene has not yet been taken to its ultimate and practical conclusion, and only by in vivo studies can it be taken there. The results from the proposed studies will provide a groundwork for treating human cancer not only with the retinoblastoma gene but also with a large number of newly discovered tumor suppressor genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA058318-05
Application #
2414250
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Marks, Cheryl L
Project Start
1992-05-01
Project End
2000-04-30
Budget Start
1997-05-01
Budget End
2000-04-30
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Miscellaneous
Type
Other Domestic Higher Education
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Chen, Yumay; Riley, Daniel J; Zheng, Lei et al. (2002) Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem 277:49408-16
Durfee, T; Mancini, M A; Jones, D et al. (1994) The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing. J Cell Biol 127:609-22
Mancini, M A; Shan, B; Nickerson, J A et al. (1994) The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. Proc Natl Acad Sci U S A 91:418-22
Riley, D J; Lai, C C; Chang, C Y et al. (1994) Susceptibility to tumors induced in mice by ethylnitrosourea is independent of retinoblastoma gene dosage. Cancer Res 54:6097-101
Hensey, C E; Hong, F; Durfee, T et al. (1994) Identification of discrete structural domains in the retinoblastoma protein. Amino-terminal domain is required for its oligomerization. J Biol Chem 269:1380-7
Chang, C Y; Riley, D J; Lee, E Y et al. (1993) Quantitative effects of the retinoblastoma gene on mouse development and tissue-specific tumorigenesis. Cell Growth Differ 4:1057-64
Bignon, Y J; Chen, Y; Chang, C Y et al. (1993) Expression of a retinoblastoma transgene results in dwarf mice. Genes Dev 7:1654-62